Barr COO leaves
This article was originally published in The Tan Sheet
Barr Phamaceuticals' President and Chief Operating Officer Paul M. Bisaro announces Aug. 2 he is leaving the company to work for Watson Pharmaceuticals. Barr's Chairman and CEO Bruce L. Downey will assume Bisaro's responsibilities in the interim period. The Woodcliff Lake, N.J.-based firm says it is "confident that the departure will not have a negative effect on U.S. or international operations"...
You may also be interested in...
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.